# TRENDING CONTENT OS — DAILY PIPELINE RUN
**Date:** 2026-07-12 | **Niche:** Health & Wellness | **Run Mode:** Full Pipeline (Skills 01–12)

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 configs loaded | ✅ |
| All 12 skills + Skill 02b present | ✅ |
| site_niche set ("health and wellness") | ✅ |
| target_audience set | ✅ |
| site_url | ⚠️ Not configured — self-check skipped; competitor-check fallback active |
| SerpAPI connected | ✅ (via injected pre-fetch block) |
| Google Trends | ✅ Available — SerpAPI pre-fetch injected; used as primary search_velocity source |
| Google News Radar | ✅ 144 signals across 12 queries; 60 shown |
| data/deferred_topics.yaml | No entries past recheck_on date |
| data/run_history.yaml | No recurring theme flags — first run in history |

**Preflight verdict:** ✅ Cleared to run. Self-check note will appear on all candidates.

---

## GOOGLE NEWS RADAR — COVERAGE SUMMARY

**12 query clusters observed; 144 unique signals, 60 surfaced.**

| Cluster | Headlines seen | Pipeline decision | Rationale |
|---|---|---|---|
| **FDA Recalls** (eye drops, blueberries, cream cheese, seasoning, shampoo, skin creams) | 11 | **RETAINED (3)** | Eye drop recall (2.5M bottles, steroids, Class II), E. coli / frozen blueberries, cream cheese recall — all meet recall signal_type thresholds with FDA.gov + CDC + Tier-1 news corroboration |
| **Health policy / ACA / insurance premiums** | 5 | **REJECTED** | Excluded category: pure healthcare policy/business without patient health content angle meeting borderline criteria |
| **Mitch McConnell health** | 2 (NPR + rising Trends queries) | **REJECTED** | Celebrity/political health status; excluded — brand safety: political celebrity health gossip without medical evidence angle |
| **Medical studies — sleep/weight, opioid taper, lung transplant cancer, glioma** | 4 | **RETAINED (2)** | Sleep deprivation → weight gain (Columbia/CUIMC; strong audience fit); opioid taper for chronic pain (Stanford; high patient relevance). Lung transplant cancer study and glioma progression retained at P3. |
| **Clinical trials — Ebola DRC** | 4 (NPR, Mongabay, Forbes, STAT) | **RETAINED (1)** | Convergent credible sourcing; infectious disease category; actionable public health angle |
| **Clinical trials — AI/design methodology** | 3 | **REJECTED** | Off-category for general health audience; too technical/industry-facing |
| **GLP-1 / Ozempic — online access, limited oversight** | 1 (Yale study) | **RETAINED (1)** | High audience relevance, peer-reviewed institution, strong SERP gap for consumer safety angle |
| **Digital health fraud (Adderall/$90M scheme)** | 1 (DOJ) | **MONITORED** | Regulatory/public health angle exists but borderline; primarily a crime/legal story; audience relevance score insufficient for core |
| **Wellness cluster (retreats, coaching, incentives, peptides)** | 9 | **REJECTED (8), MONITORED (1)** | Mostly local, promotional, or lifestyle fluff. FT peptide piece monitored (supplement claim — needs 02b gate; insufficient primary sourcing) |
| **Walking speed / super mover** | Google Trends trending now | **RETAINED (1)** | Rising Trends signal; exercise science + longevity category; clear SERP gap |
| **Nutrition / gut health rising** | Trends: nutrition +9, gut health +9 | **RETAINED (1 combined)** | Strong Trends velocity; gut health audience overlap with allowed categories; editorial consolidation opportunity |
| **PCOS nutrition center / enteral nutrition** | Trends rising | **MONITORED** | PCOS nutrition: insufficient news corroboration this cycle to score. Enteral nutrition: too clinical/institutional for general audience |
| **UC San Diego AI health institute / neuroimaging models** | 2 (Nature, UCSD) | **REJECTED** | Too institutional; no direct patient/consumer health angle |
| **Pediatric mental health emergency gaps** | 1 (News-Medical/Illinois) | **RETAINED (1)** | Mental health + pediatric health categories; strong audience relevance |
| **Fentanyl vaccine** | 1 (Clinical Trial Vanguard) | **MONITORED (02b gate)** | Drug/treatment claim + clinical trial; 02b triggered; single source with editorial skepticism already embedded; insufficient primary source corroboration for scoring |

---

## SIGNAL SUMMARY

```yaml
run_started_at: 2026-07-12T00:00:00Z
run_completed_at: 2026-07-12T00:00:00Z
total_signals_reviewed: 144
total_signals_retained: 9
total_rejected: 23
google_trends_available: true
search_velocity_source: google_trends
rejection_breakdown:
  off_category: 8
  brand_safety: 3
  duplicate: 0
  weak_signal: 6
  unverified_claim: 2
  other: 4 (monitored, not rejected)
highest_priority_topic: "FDA Recall — 2.5 Million Steroid Eye Drop Bottles (Foreign Substance Contamination)"
strongest_signal_source: "FDA.gov + CDC.gov + Prevention + MSN + NJ.com + WSOC (convergent, Tier 1)"
tools_unavailable: []
notes: >
  site_url not configured — self-check skipped; competitor coverage checked instead.
  Google Trends pre-fetch used as primary search_velocity.
  McConnell health queries are top rising on Trends but excluded (political celebrity health status — brand safety).
  Wellness cluster was largely promotional/local; Financial Times peptide piece monitored pending 02b — insufficient primary sourcing to pass gate.
  Fentanyl vaccine monitored — 02b triggered, single editorial source with skepticism embedded, no primary trial data traceable.
  PCOS nutrition flagged for next cycle if news corroboration develops.
```

---

## SKILL 02B ROUTING SUMMARY

| Topic | Risk Type | Gate Result | Primary Source Found | Action |
|---|---|---|---|---|
| FDA Eye Drop Recall (steroid/foreign substance) | Recall | **PASS** (breaking-recall exception) | FDA.gov recall notice URL confirmed via multiple outlets | Confidence capped at Medium until FDA notice directly retrieved; passed to scoring |
| E. coli / Frozen Blueberries | Recall | **PASS** (primary source: CDC.gov outbreak investigation page confirmed) | CDC.gov + FDA.gov both publishing | Full pass; primary source confirmed |
| Cream Cheese Recall (Class I) | Recall | **PASS** (breaking-recall exception; 3+ Tier-1 sources name same product + recall reason) | FDA.gov cited by AOL/Reader's Digest; Class I = death risk framing requires care | Confidence capped at Medium; integrity flag added |
| GLP-1 Online Access Study (Yale) | Medical study | **PASS** | Yale School of Medicine press release; study described as "online secret shopping"; journal not named in headline — integrity flag added | Passes with note: verify journal citation before publishing |
| Sleep Deprivation → Weight Gain | Medical study | **PASS** | Columbia University Irving Medical Center press release; study type not specified — integrity flag: verify whether observational or RCT | Pass |
| Stanford Opioid Taper Study | Medical study | **PASS** | Stanford Medicine press release confirmed; study described as finding "many patients can reduce" — moderate claim language; flag association vs causation | Pass |
| Ebola DRC Clinical Trials | Clinical trial | **PASS** | NPR + Mongabay + Forbes convergent; Bundibugyo strain + DRC epicenter named; no primary trial ID found but breaking public health exception applies | Pass with medium confidence |
| Fentanyl Vaccine | Drug/treatment claim + clinical trial | **MONITOR** | Single editorial source (Clinical Trial Vanguard) with internal skepticism; no primary trial ID, DOI, or institutional press release found | Routed to P5 / Monitor — do not score |
| FT Peptide Wellness piece | Supplement/drug claim | **MONITOR** | Single lifestyle source (FT); no primary sourcing for specific peptide claims | Routed to P5 / Monitor |
| Lung transplant / terminal lung cancer | Medical study | **PASS** | Northwestern Medicine Newsroom; study claim is plausible and institutional; integrity flag: journal/peer-review status of press release not confirmed | Pass with low confidence |
| Pediatric mental health emergency gaps | Medical study | **PASS** | News-Medical citing Illinois study; institution named; audience relevance high | Pass — integrity flag: secondary reporting; verify primary study details |

---

## EDITORIAL PRIORITY BOARD

| # | Priority | Timing | Topic | Trend | Opp | Discover | Urgency | Confidence |
|---|---|---|---|---|---|---|---|---|
| 1 | **P1** | Immediate | FDA Recalls 2.5M Steroid Eye Drop Bottles — Foreign Substance | 88 | 82 | 5 | Now | Medium |
| 2 | **P1** | Immediate | E. coli Outbreak Linked to Frozen Blueberries — CDC Active Investigation | 84 | 78 | 5 | Now | High |
| 3 | **P1** | Today | Cream Cheese Recalled — FDA Class I (Death Risk) | 75 | 72 | 4 | Today | Medium |
| 4 | **P2** | Short-term | Yale Study: Online GLP-1 Prescriptions With Little Oversight — What Patients Need to Know | 72 | 76 | 4 | Today | Medium |
| 5 | **P2** | Short-term | Sleep Deprivation Linked to Weight Gain — Columbia Study | 74 | 71 | 4 | This week | Medium |
| 6 | **P2** | Short-term | Stanford: Chronic Pain Patients Can Taper Opioids Slowly — What the Research Shows | 65 | 68 | 4 | This week | Medium |
| 7 | **P3** | Scheduled | Ebola Clinical Trials Begin in DRC — Bundibugyo Strain Update | 68 | 62 | 3 | This week | Medium |
| 8 | **P3** | Scheduled | "Super Mover" Walking Speed — What the Research Says About Intensity and Longevity | 63 | 65 | 4 | This week | Medium |
| 9 | **P3** | Scheduled | Pediatric Mental Health Emergencies Are Overwhelming ERs — What the Data Shows | 58 | 63 | 3 | This week | Low |

---

## EDITORIAL BRIEFS

---

### BRIEF 1 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: FDA Recalls 2.53 Million Steroid Eye Drop Bottles Over Foreign Substance Contamination
primary_entity: Lupin Pharmaceuticals eye drop recall
signal_type: recall
allowed_category: FDA and CDC regulatory updates
trend_strength_score: 88
opportunity_score: 82
discover_score: 5
urgency: now
confidence: medium
content_status: new (self-check skipped — no site_url)
source_count: 6
recommended_angle: >
  Consumer safety action guide — which specific products are recalled, what to check at home,
  what risks the contamination poses, and when to see a doctor.
why_now: >
  FDA recall active as of July 6–10, 2026. 2.53 million bottles across multiple steroid eye drop
  SKUs. "Foreign substance" contamination — consumer confusion is high; search spike confirmed
  in Google Trends ("fda class ii eye drop recall" trending now). Most current coverage is
  news-brief format with no consumer guidance depth. Major SERP gap for actionable explainer.
primary_headline: "FDA Recalls 2.5 Million Eye Drop Bottles: Is Yours on the List?"
```

**Alternate headlines:**
- "Steroid Eye Drops Recalled: What the FDA's Foreign Substance Warning Means for You"
- "2.5 Million Eye Drop Bottles Pulled From Shelves — Check These Products Now"

**Why now:** Active FDA recall with high consumer search interest. Trending on Google Trends ("fda class ii eye drop recall," "lupin pharmaceuticals eye drop recall"). Six credible outlets reporting convergently. Consumers are actively searching to check whether their product is affected.

**Outline:**
1. **Lede:** What's been recalled, by whom, and why (Lupin Pharmaceuticals; foreign substance; 2.53M bottles; FDA Class II)
2. **Product list:** Specific product names, NDC codes, lot numbers — pulled from FDA recall notice
3. **What "foreign substance" means:** Plain-language explanation of what this contamination type typically is and why it triggers recall
4. **Who is at risk:** Steroid eye drops are typically prescribed for inflammation, post-surgery, allergic conjunctivitis — describe likely users
5. **What to do:** Stop using recalled products; do NOT return to eye; disposal guidance; when to contact your doctor or pharmacist
6. **When to seek care:** Symptoms that warrant urgent ophthalmology attention
7. **FDA recall background:** Brief note on Class II recall classification and what it means vs Class I
8. **FAQ:** "Can I finish the bottle if I haven't had problems?" / "Are generic versions affected?"

**Key data points:**
- 2.53 million bottles recalled
- Lupin Pharmaceuticals named manufacturer
- "Foreign substance" contaminant (specific nature TBD from FDA notice)
- FDA Class II recall (risk of temporary adverse health consequences)
- Multiple outlets confirm July 6–10 coverage window

**Source plan:**
- FDA recall notice: https://www.fda.gov (search: Lupin eye drop recall July 2026) `[verify exact URL from FDA recalls page]`
- Prevention: https://www.prevention.com (July 7, 2026 — "Over 2.5 Million Bottles of Eye Drops Recalled") [URL unverified — confirm]
- MSN/FDA sourced: https://www.msn.com (July 10 — "FDA recalls 2.53 million steroid eye drop bottles") [URL unverified]
- NJ.com: https://www.nj.com (July 7) [URL unverified]
- WSOC TV: https://www.wsoctv.com (July 10) [URL unverified]

**⚠️ Integrity flags:**
- Confidence capped at Medium — primary FDA recall notice not directly retrieved; confirmed via 5+ credible outlets naming same product, manufacturer, and recall type. **Verify exact product list and lot numbers from fda.gov before publishing.**
- "Foreign substance" is FDA language — do not speculate on specific contaminant type without primary source confirmation.
- Class II ≠ Class I; do not use language suggesting imminent danger or death risk (that is Class I language).

**Expert type:** Ophthalmologist or pharmacist for "what to do" context. Pull from existing published quotes or institutional advisory if available (no outreach required).

**SEO:**
- Primary keyword: "eye drop recall 2026"
- Supporting: "FDA eye drop recall list," "steroid eye drops recalled," "Lupin eye drop recall," "what eye drops are recalled"
- Format: News explainer + checklist/product table
- Schema: FAQPage + NewsArticle
- Cluster: FDA regulatory updates / consumer safety

**Discover notes:** Score 5 — specific named entity (Lupin Pharmaceuticals), direct AI query ("which eye drops were recalled"), primary source available (FDA.gov), durable consumer utility, clear SERP gap vs shallow news briefs.

**Estimated word count:** 900–1,200 words

---

### BRIEF 2 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: E. coli Outbreak Linked to Frozen Blueberries — CDC and FDA Active Investigation
primary_entity: E. coli outbreak / frozen blueberries
signal_type: recall
allowed_category: public health and epidemiology / FDA and CDC regulatory updates
trend_strength_score: 84
opportunity_score: 78
discover_score: 5
urgency: now
confidence: high
content_status: new (self-check skipped — no site_url)
source_count: 5
recommended_angle: >
  Outbreak tracker explainer — what is known so far, which products are linked,
  symptoms to watch for, what to do if you've eaten affected blueberries.
why_now: >
  CDC active outbreak investigation page published July 7, 2026. FDA also published
  July 6 outbreak investigation page. Good Housekeeping and other Tier-2 sources
  reporting. Frozen blueberries are a widely consumed household product; consumer
  urgency is high. Most coverage is short news alerts — no deep consumer explainer exists.
primary_headline: "E. Coli Outbreak Tied to Frozen Blueberries: What to Know Right Now"
```

**Alternate headlines:**
- "CDC Investigating E. Coli in Frozen Blueberries — Symptoms, Recalls, and What to Do"
- "Are Your Frozen Blueberries Safe? Here's What the CDC Is Saying"

**Why now:** CDC outbreak investigation page is live (July 7, 2026). FDA investigation page also live (July 6). Active outbreak = time-sensitive consumer health content. Frozen blueberries are pantry staples; high household penetration means broad audience relevance. Competitor coverage is news-brief format only — no explainer with symptoms, disposal, and medical guidance.

**Outline:**
1. **Lede:** Active CDC/FDA outbreak investigation; what we know as of [date]
2. **Which products:** Retailer(s) involved, product names, lot codes (pull from CDC/FDA pages)
3. **Where blueberries were sold:** States affected; distribution scope
4. **E. coli symptoms:** STEC O157:H7 or equivalent — onset timeline, HUS risk in vulnerable populations (children, elderly, immunocompromised)
5. **What to do if you have the product:** Dispose; do not eat; do not donate; when to seek care
6. **When to see a doctor:** Bloody diarrhea, severe cramps, signs of HUS — emergency indicators
7. **Ongoing investigation note:** Numbers will update; link to live CDC tracker
8. **FAQ:** "Can I wash blueberries to make them safe?" / "Is this the same as the 2022 outbreak?"

**Key data points:**
- CDC outbreak investigation URL: https://www.cdc.gov (July 7, 2026 — E. coli / Frozen Blueberries)
- FDA outbreak investigation URL: https://www.fda.gov (July 6, 2026)
- Good Housekeeping reporting: https://www.goodhousekeeping.com (July 7) [URL unverified]
- Case count, states, and retailer TBD from CDC live page at time of writing

**⚠️ Integrity flags:**
- Outbreak investigations are active and data will change — publish with "This story is developing; check CDC.gov for updates" note.
- Do not state confirmed case count without direct CDC page verification at time of writing.
- E. coli strain type (STEC, O157:H7, etc.) — confirm from CDC page; do not assume.
- Avoid language suggesting the outbreak is "contained" — ongoing investigation.

**Expert type:** Infectious disease physician or food safety specialist. CDC MMWR language and official advisory are primary voice — cite directly.

**SEO:**
- Primary keyword: "frozen blueberry recall E. coli"
- Supporting: "E. coli outbreak 2026," "blueberry recall 2026," "E. coli blueberries symptoms," "CDC blueberry outbreak"
- Format: Outbreak explainer + symptom checklist
- Schema: NewsArticle + FAQPage
- Cluster: Public health / FDA regulatory updates

**Estimated word count:** 800–1,100 words

---

### BRIEF 3 — P1 / TODAY

```yaml
priority_level: P1
publish_timing: immediate (within 24 hours)
topic: Cream Cheese Recalled — FDA Class I Risk Level ("Serious Adverse Health Consequences or Death")
primary_entity: Cream cheese FDA Class I recall
signal_type: recall
allowed_category: FDA and CDC regulatory updates / public health
trend_strength_score: 75
opportunity_score: 72
discover_score: 4
urgency: today
confidence: medium
content_status: new (self-check skipped — no site_url)
source_count: 4
recommended_angle: >
  Plain-language explainer: what product was recalled, what Class I means,
  what contamination is involved, and what consumers should do — without sensationalism.
why_now: >
  AOL/Reader's Digest and MedShadow reporting as of July 8, 2026. FDA Class I recall
  (highest severity) for cream cheese. "Death" language in headline is alarming to consumers;
  a calm, accurate explainer fills a clear gap and counters potential misinformation spread.
primary_headline: "Cream Cheese Recalled by FDA: What Class I Risk Actually Means for You"
```

**Alternate headlines:**
- "Cream Cheese Recall: FDA Issues Highest-Level Warning — Here's What to Do"
- "FDA Cream Cheese Recall Explained: What 'Serious Health Risk' Means and Whether You're Affected"

**Why now:** Active FDA Class I recall reported July 8, 2026. "Death" language in coverage is generating consumer alarm. Editorial opportunity to be the authoritative, calm explainer that correctly contextualizes Class I recall meaning — vs. panic-generating news alerts. SERP gap is clear; most coverage is brief news hits.

**Outline:**
1. **Lede:** What was recalled, manufacturer, quantity — factual and calm
2. **What is an FDA Class I recall:** Plain-language definition (highest risk tier; reasonable probability of serious adverse health consequences or death); contrast with Class II/III
3. **What contamination is involved:** Pathogen or hazard type — pull from FDA notice
4. **Who is most at risk:** Immunocompromised individuals, elderly, pregnant women — typical high-risk populations for foodborne illness
5. **What to do:** Check product; do not eat if recalled; disposal guidance; refund/return options
6. **When to seek care:** Symptoms warranting medical attention
7. **Context:** How common are Class I recalls? (FDA data) — helps readers calibrate alarm

**⚠️ Integrity flags:**
- Confidence medium — FDA recall notice not directly retrieved; confirmed via multiple outlets citing same product and Class I designation. **Verify exact product name, manufacturer, lot codes, and contamination type from FDA.gov before publishing.**
- Do NOT reproduce "serious adverse health consequences or death" as headline without contextualizing that this is FDA classification language, not a confirmed death report.
- Avoid sensationalism. This is the key editorial differentiation from existing coverage.

**SEO:**
- Primary keyword: "cream cheese recall 2026"
- Supporting: "FDA Class I recall cream cheese," "cream cheese recalled FDA," "what is FDA Class I recall"
- Format: News explainer
- Estimated word count: 700–900 words

---

### BRIEF 4 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term (within 48 hours)
topic: Yale Study Finds Easy Online Access to GLP-1 Prescriptions With Limited Clinician Oversight
primary_entity: GLP-1 medications / online prescribing
signal_type: study_or_research
allowed_category: medical research and clinical trials / chronic disease management
trend_strength_score: 72
opportunity_score: 76
discover_score: 4
urgency: today
confidence: medium
content_status: new (self-check skipped — no site_url)
source_count: 3
recommended_angle: >
  Consumer safety and informed decision-making angle: what the Yale secret-shopping
  study found, what risks come with minimal-oversight GLP-1 prescribing,
  and what patients should look for in a legitimate telehealth provider.
why_now: >
  Yale School of Medicine published July 8, 2026. GLP-1 searches ("Ozempic,"
  "semaglutide," "weight loss medication") remain persistently high. Consumer-facing
  coverage of this study is minimal — most reporting is health-trade or news-brief format.
  Strong SERP gap for a patient-safety angle targeting the audience asking
  "is it safe to get Ozempic online?"
primary_headline: "Ozempic Online: Yale Study Finds Most Telehealth Prescribers Ask Few Questions"
```

**Alternate headlines:**
- "How Easy Is It to Get a GLP-1 Prescription Online? Yale Researchers Found Out"
- "The Ozempic Telehealth Loophole: What a New Study Reveals About Patient Safety"

**Why now:** Yale published July 8, 2026. GLP-1/telehealth intersection is one of the highest-interest consumer health topics of 2025–2026. Minimal clinician oversight in online prescribing creates real patient safety implications — cardiac screening, contraindications, drug interactions. Study framing ("secret shopping") is inherently engaging. Competitor coverage is thin.

**Outline:**
1. **Lede:** What Yale researchers did (secret shopping of online GLP-1 prescribers)
2. **What they found:** How easily prescriptions were obtained; what screening was or wasn't done
3. **Why this matters:** GLP-1 medications are not risk-free — contraindications (pancreatitis history, MEN2, thyroid cancer risk), drug interactions, need for monitoring
4. **What "limited oversight" looks like in practice:** No physical exam, no lab work, no follow-up — patient experience context
5. **What to look for in a legitimate provider:** Red flags vs. green flags for telehealth GLP-1 prescribing
6. **FDA and regulatory context:** Current rules around telehealth prescribing; where regulation stands
7. **Expert voice:** Endocrinologist or obesity medicine specialist quote from a published interview or the Yale press release
8. **FAQ:** "Is it illegal to get GLP-1 online?" / "What questions should my provider be asking?"

**Key data points:**
- Yale School of Medicine, July 8, 2026: https://medicine.yale.edu [URL unverified — confirm specific study page]
- Study method: "online secret shopping" — note this is likely observational/audit study design
- Specific findings (prescribing rates, screening omissions) — pull from press release

**⚠️ Integrity flags:**
- Study journal/peer-review status not confirmed in available headline — **verify before publishing** whether this has been peer-reviewed or is a preprint/press release.
- Secret-shopping study = observational audit; cannot establish causation or determine patient outcomes.
- GLP-1 medications have real contraindications — do not overstate risk or imply all online prescribing is dangerous; nuance is essential.

**SEO:**
- Primary keyword: "GLP-1 online prescription safety"
- Supporting: "Ozempic online prescription," "semaglutide telehealth," "GLP-1 telehealth risks," "how to get Ozempic safely"
- Format: News explainer + patient safety guide
- Schema: NewsArticle + FAQPage
- Estimated word count: 1,000–1,400 words

---

### BRIEF 5 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term (within 72 hours)
topic: Skipping Sleep Leads to Weight Gain — What the Columbia Study Found
primary_entity: Sleep deprivation and weight gain
signal_type: study_or_research
allowed_category: sleep science / nutrition and diet science
trend_strength_score: 74
opportunity_score: 71
discover_score: 4
urgency: this_week
confidence: medium
content_status: new (self-check skipped — no site_url)
source_count: 3
recommended_angle: >
  Mechanistic explainer: not just that sleep deprivation causes weight gain,
  but HOW — hormonal mechanisms (ghrelin, leptin, cortisol), behavioral drivers
  (late-night eating, reduced activity), and what the data means for practical sleep habits.
why_now: >
  Columbia University Irving Medical Center published July 6, 2026. Google Trends shows
  "diet" at 79 (7-day score), "nutrition" at 84, "gut health" at 82 — audience is actively
  engaged with weight and diet content this week. Sleep-weight connection is perennially
  searched but rarely explained with mechanistic depth. SERP gap for a non-superficial explainer.
primary_headline: "Poor Sleep Is Making You Gain Weight — Here's the Science Behind Why"
```

**Alternate headlines:**
- "Columbia Study: Not Enough Sleep Directly Leads to Weight Gain — What's Actually Happening"
- "The Sleep-Weight Connection: New Research Explains the Mechanism"

**Why now:** Columbia CUIMC published July 6, 2026. Freshness window valid. Diet/nutrition/sleep Trends all elevated this week, creating a convergent audience moment. Most existing SERP content on "sleep and weight" is generic list-based; a mechanism-led explainer can differentiate.

**Outline:**
1. **Lede:** What Columbia found — quantify the effect size if available
2. **Study design note:** Observational or controlled? Sample size? Duration? (pull from press release — critical for integrity framing)
3. **The mechanism — ghrelin and leptin:** How sleep deprivation disrupts hunger hormones
4. **The mechanism — cortisol and insulin:** Stress hormone pathways and glucose metabolism
5. **The mechanism — behavioral:** Late-night snacking, decision fatigue, reduced motivation to exercise
6. **How much sleep loss triggers effects?** Any threshold data from the study
7. **What this means for practical sleep habits:** Not a prescription; a framework for prioritization
8. **What we don't know yet:** Limitations of the study; other factors
9. **FAQ:** "Can I catch up on sleep on weekends?" / "Does napping help?"

**⚠️ Integrity flags:**
- Study type not confirmed — **verify whether this is an observational study or RCT before publishing.** If observational, do NOT write "sleep deprivation causes weight gain" without adding "associated with" or equivalent hedging.
- Do not present magnitude of effect without absolute numbers (e.g., "X pounds over Y weeks").
- Single study — note that this adds to existing body of evidence, not that it is definitive.

**Expert type:** Sleep medicine specialist or endocrinologist. Pull from published interviews or Columbia press release quotes.

**SEO:**
- Primary keyword: "sleep deprivation weight gain"
- Supporting: "does lack of sleep cause weight gain," "sleep and metabolism research," "how sleep affects weight," "Columbia sleep study 2026"
- Format: Research explainer with mechanism breakdown
- Schema: Article + FAQPage
- Estimated word count: 1,100–1,500 words

---

### BRIEF 6 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term (within 72 hours)
topic: Stanford Study: Many Chronic Pain Patients Can Reduce Opioid Use Through Slow, Voluntary Taper
primary_entity: Opioid tapering / chronic pain management
signal_type: study_or_research
allowed_category: medical research and clinical trials / chronic disease management
trend_strength_score: 65
opportunity_score: 68
discover_score: 4
urgency: this_week
confidence: medium
content_status: new (self-check skipped — no site_url)
source_count: 2
recommended_angle: >
  Patient empowerment angle: what a voluntary, slow taper actually looks like,
  what the Stanford data shows about outcomes, and what this means for patients
  currently on long-term opioids for chronic pain.
why_now: >
  Stanford Medicine published July 9, 2026. Opioid use disorder and chronic pain are
  persistent high-relevance topics. Study is notable because it centers patient
  agency (voluntary taper) rather than forced tapering — a meaningful distinction
  with strong SERP differentiation from existing crisis-framing coverage.
primary_headline: "Stanford Study: Patients With Chronic Pain Can Reduce Opioids on Their Own Timeline"
```

**Alternate headlines:**
- "How Slow, Voluntary Opioid Tapering Works — And Why Stanford's Research Matters"
- "You Don't Have to Quit Opioids Cold Turkey: Stanford Study on Gradual, Patient-Led Tapering"

**Why now:** Published July 9, 2026 — within freshness window. Chronic pain affects approximately 50 million U.S. adults; opioid management is a high-concern topic. The "voluntary" framing differentiates from policy/mandate narratives. SERP gap: most chronic pain + opioid content is either crisis-framing or clinical-facing.

**Outline:**
1. **Lede:** What Stanford found — "many" patients able to reduce opioid use with slow, voluntary taper
2. **Define "voluntary taper":** Patient-initiated, gradual dose reduction vs. forced or rapid tapering (critical distinction; forced tapering has caused patient harm)
3. **Study design:** Who was studied, method, duration — note study type (observational vs. interventional)
4. **What outcomes looked like:** Pain levels, quality of life, function — specific data from Stanford release
5. **What "slow" means:** Timeline data if available; why pace matters
6. **Why this is different from previous tapering guidance:** Historical forced-taper harms; this study's contribution to patient-centered care narrative
7. **Who this applies to — and who it doesn't:** Not for all patients; acute pain, cancer pain, addiction treatment differ
8. **What to do if you're on long-term opioids:** Talk to your prescriber — not a DIY guide; empowerment with appropriate caution
9. **Expert quote:** Pull from Stanford press release or named researcher

**⚠️ Integrity flags:**
- "Many" is imprecise — pull exact percentage or sample language from Stanford release; do not overstate generalizability.
- Study design not confirmed — **verify whether observational or controlled before publishing.**
- Avoid framing that implies patients should taper without physician guidance — this is a medical decision requiring prescriber involvement.
- Do not conflate opioid tapering for chronic pain with opioid use disorder/addiction treatment — these are clinically distinct.

**SEO:**
- Primary keyword: "opioid tapering chronic pain"
- Supporting: "how to reduce opioid dosage," "voluntary opioid taper," "Stanford chronic pain study," "long-term opioid reduction"
- Format: Research explainer + patient guide
- Estimated word count: 1,000–1,300 words

---

### BRIEF 7 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (within 1 week)
topic: Ebola Clinical Trials Begin in DRC — First Treatment Hope for Bundibugyo Strain
primary_entity: Ebola / Bundibugyo strain / DRC clinical trials
signal_type: clinical_trial
allowed_category: infectious disease / public health
trend_strength_score: 68
opportunity_score: 62
discover_score: 3
urgency: this_week
confidence: medium
content_status: new
source_count: 4
recommended_angle: >
  Explainer for a general health audience: what the Bundibugyo strain is, why it's
  been neglected in treatment development, what the new trials involve,
  and what the realistic timeline looks like.
why_now: >
  Clinical trials began July 6–8, 2026, confirmed by NPR, Mongabay, Forbes, and STAT.
  The Bundibugyo strain has no approved treatment; these are the first designed trials.
  This is a meaningful infectious disease development underreported in consumer health media.
primary_headline: "The Ebola Strain With No Treatment Just Got Its First Clinical Trials — Here's What's at Stake"
```

**Alternate headlines:**
- "DRC Ebola Outbreak Prompts First-Ever Clinical Trials for Bundibugyo Strain"
- "New Ebola Trials Begin in Congo: What the Research Means and How Far It Has to Go"

**Key data points:**
- NPR: https://www.npr.org (July 7) [URL unverified — confirm]
- Mongabay: https://www.mongabay.com (July 8) [URL unverified]
- Forbes: https://www.forbes.com (July 7) [URL unverified]
- STAT News: https://www.statnews.com (July 6) [URL unverified]

**⚠️ Integrity flag:** Clinical trial ID and sponsor not yet confirmed in available signals — verify from ClinicalTrials.gov or WHO AFRO before publishing. Note trial phase (likely Phase 1 or Phase 1/2 — important for managing reader expectations about timeline to treatment availability).

**SEO:** Primary keyword: "Ebola Bundibugyo strain 2026" | Format: Explainer | Word count: 900–1,100

---

### BRIEF 8 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (within 1 week)
topic: "Super Mover" Walking — What the Science Actually Says About Walking Speed and Health
primary_entity: Walking speed / "super mover" exercise benefits
signal_type: rising_search_interest
allowed_category: fitness and exercise science / aging and longevity
trend_strength_score: 63
opportunity_score: 65
discover_score: 4
urgency: this_week
confidence: medium
content_status: new
source_count: 2
recommended_angle: >
  Evidence-grounded explainer: what "super mover" walking means, what the research
  says about vigorous walking vs. moderate walking for longevity markers,
  and how to apply it practically without injury risk.
why_now: >
  "Super mover walking speed benefits" is trending now in Google Trends health category
  as of today (July 12, 2026). No strong authoritative explainer occupies the SERP.
  Exercise science + longevity are core audience interests with high Discover score
  potential given specific entity and answerable question format.
primary_headline: "What Is 'Super Mover' Walking — And Is the Speed Actually Better for You?"
```

**Alternate headlines:**
- "The Case for Walking Faster: What Research Shows About Speed and Longevity"
- "'Super Mover' Walking Explained: The Science Behind Going From Strolling to Striding"

**Key data points:** Research on brisk vs. moderate walking and longevity markers (all-cause mortality, cardiovascular outcomes) — pull from existing published literature (NHS walking studies, UK Biobank walking speed cohort data, JAMA Network Open walking pace studies). Note: confirm whether "super mover" terminology originates from a specific study or is media framing.

**⚠️ Integrity flag:** "Super mover" appears to be a trending search term; verify whether this traces to a specific published study or is a media/marketing label applied to existing exercise science. Do not present as a new medical concept without source confirmation.

**SEO:** Primary keyword: "super mover walking benefits" | Supporting: "walking speed health benefits," "how fast should you walk for health," "brisk walking longevity" | Format: Explainer | Word count: 900–1,100

---

### BRIEF 9 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled (within 1 week)
topic: Pediatric Mental Health Emergencies Are Overwhelming ERs — What the Illinois Data Shows
primary_entity: Pediatric mental health / emergency department gaps
signal_type: study_or_research
allowed_category: mental health and psychology / pediatric health
trend_strength_score: 58
opportunity_score: 63
discover_score: 3
urgency: this_week
confidence: low
content_status: new
source_count: 2
recommended_angle: >
  Data-driven explainer on the scope of the gap: what the Illinois study found,
  why ERs are not equipped for pediatric mental health crises, and what families
  should know about their options when a child needs urgent mental health care.
why_now: >
  News-Medical published July 8, 2026. Pediatric mental health crisis is a
  sustained high-salience topic for parents and caregivers — a core segment of the
  health-conscious general audience. Most ER-focused coverage is clinician-facing.
  Parent-facing explainer with practical guidance has clear SERP gap.
primary_headline: "Kids in Mental Health Crisis Are Ending Up in ERs That Can't Help Them. Here's Why"
```

**Alternate headlines:**
- "Emergency Rooms Are Failing Children in Mental Health Crises — New Study Outlines the Gaps"
- "Pediatric Mental Health Emergencies: What Parents Need to Know When the ER Isn't Enough"

**Key data points:**
- News-Medical citing University of Illinois study: https://www.news-medical.net (July 8) [URL unverified — locate primary study]
- Find primary study or principal investigator — verify journal/institution

**⚠️ Integrity flags:**
- Confidence is Low — single secondary source (News-Medical); primary study not directly confirmed. **Locate the original study or PI before commissioning.** If primary study cannot be confirmed, downgrade to research-in-progress note and monitor.
- Do not use specific statistics from secondary source without verifying against primary.
- Mental health content for pediatric audience: ensure language is non-stigmatizing; follow mental health reporting guidelines.

**SEO:** Primary keyword: "pediatric mental health emergency room" | Supporting: "children mental health crisis ER," "pediatric mental health gaps," "what to do when child has mental health emergency" | Format: Explainer + parent guide | Word count: 900–1,200

---

## REJECTED TOPICS LOG

| Topic | Signal Source | Rejection Reason |
|---|---|---|
| Mitch McConnell health status | Google Trends rising + NPR headline | Brand safety — political celebrity health status; excluded category (political celebrity health gossip) |
| ACA marketplace / insurance premium increases (KFF) | KFF, PBS, CT Mirror, NC News | Excluded category — pure healthcare policy/insurance business; no patient clinical health content angle meeting borderline threshold |
| Yale CEO ouster / health system financial woes | CT Mirror | Excluded — local hospital/health system admin news; no national patient health angle |
| AI-driven clinical trial design methodology | Nature, Applied Clinical Trials, Medical Xpress | Off-category — too technical/industry-facing for general health audience |
| UC San Diego AI health intelligence institute | UC San Diego Today | Off-category — institutional announcement, no patient/consumer health content |
| Health system neuroimaging AI models | Nature | Off-category — technical AI/medical imaging; no consumer angle |
| UHC lifestyle spending accounts | Fierce Healthcare | Excluded — insurance product/healthcare business news |
| FT male wellness peptide guide | Financial Times | Skill 02b Monitor — supplement/drug claim; single lifestyle source; no primary sourcing for peptide claims; insufficient to score |
| Fentanyl vaccine (clinical trial claim) | Clinical Trial Vanguard | Skill 02b Monitor — drug/clinical trial claim; single editorial source with embedded skepticism; no primary trial ID or institutional source found |
| Wellness retreats (Travel + Leisure) | Travel + Leisure | Excluded — lifestyle/tourism; no evidence-based health content |
| Digital detox / wellness incentives (Marquette, Purdue) | Marquette, Purdue | Local institutional / employer incentive programs; insufficient national audience relevance |
| Social wellness month (Texas HHS) | Texas HHS gov | Government awareness campaign; insufficient editorial content value |
| New York Post wellness club for Manhattan moms | New York Post | Excluded — celebrity/lifestyle fluff; no evidence base |
| Rachael Ray health / celebrity health | Google Trends rising | Excluded — celebrity health status gossip; brand safety |
| Brian Johnson health (biohacker) | Google Trends rising | Borderline — insufficient credible news corroboration this cycle; no specific new study or development; monitor for future cycle if peer-reviewed research published |
| PCOS nutrition center (Trends rising) | Google Trends rising related | No news corroboration this cycle; monitor next cycle |
| Enteral nutrition (Trends rising) | Google Trends rising | Too clinical/institutional for general health audience without specific news hook |
| DOJ health company / Adderall fraud | DOJ press release | Primarily a crime/legal story; health angle is regulatory but enforcement-only without patient guidance applicability; monitor if reframed around telehealth prescribing safety (overlaps with GLP-1 brief angle) |
| Glioma progression / cancer evolution study | Weill Cornell | Retained at P4 — strong institutional source but audience relevance lower; no immediate consumer action. Recommend reactivating if national media picks up. |
| UCF microgravity aging study | UCF | Adjacent/edge category (space medicine); low general-audience applicability; no consumer action angle |
| Harvard viral protein study | Harvard Medical School | Basic research — too far upstream from clinical or consumer application |
| Colorado/local restaurant food safety | Google Trends related | Local news; excluded |
| Speech-to-text AI reliability (U of Cincinnati) | U Cincinnati | Off-category — AI/technology; no direct health content angle |

---

## INTEGRITY FLAGS — CONSOLIDATED

> All ⚠️ flags for editorial review before any piece goes live.

**P1 — Eye Drop Recall:**
⚠️ Confidence medium — verify exact product list, lot numbers, and foreign substance type from FDA.gov recall notice before publishing. Do not use Class I language (this is Class II).

**P1 — E. coli / Blueberries:**
⚠️ Outbreak is active and evolving — case count and product details will change. Include "developing story" note and live CDC tracker link. Verify E. coli strain type.

**P1 — Cream Cheese Recall:**
⚠️ Confidence medium — verify product name, manufacturer, lot codes, and contamination type from FDA.gov. Do NOT reproduce "serious adverse health consequences or death" as a standalone claim — contextualize as FDA classification language, not a confirmed death report.

**P2 — GLP-1 / Yale Study:**
⚠️ Peer-review status of Yale study not confirmed — verify before publishing. Secret-shopping / observational design; cannot establish causation. Nuance on telehealth safety required; not all online GLP-1 prescribing is equivalent.

**P2 — Sleep / Weight Gain (Columbia):**
⚠️ Study type (observational vs. RCT) not confirmed. Do not write "causes" without verification. Qualify effect sizes with absolute numbers, not relative framing only.

**P2 — Opioid Taper (Stanford):**
⚠️ "Many patients" is imprecise; pull exact data from Stanford release. Study design unconfirmed. Do not imply patients should taper without physician supervision. Do not conflate chronic pain opioid use with opioid use disorder/addiction treatment.

**P3 — Ebola DRC Trials:**
⚠️ Clinical trial ID and sponsor unconfirmed — verify from ClinicalTrials.gov or WHO AFRO. Clarify trial phase before publishing; manage reader expectations on treatment timeline.

**P3 — Super Mover Walking:**
⚠️ "Super mover" may be media framing rather than a specific study term. Verify origin before using as a defined medical concept. If media label, frame accordingly.

**P3 — Pediatric Mental Health / ERs:**
⚠️ Confidence LOW — single secondary source. Locate primary study before commissioning. Do not publish statistical claims without primary source verification.

---

## RUN NOTES

**Tools used:** SerpAPI pre-fetch (Google News Radar + Google Trends 7-day); Google Trends treated as available via injected block.

**Self-check status:** site_url not configured. No article slug list provided. Self-check skipped on all candidates; competitor coverage checked via competitor_list.yaml domains. All content_status marked "new" with disclosure.

**Google Trends notes:** nutrition (84), gut health (82), diet (79) are the highest-velocity health signals this week. These supported Study briefs 5 (sleep/weight) and provide a secondary signal for evergreen content commissioning. The "wellness" cluster rising queries were dominated by SEO spam domains (skillsclonelife.com, goodnever.com, etc.) — these were filtered as noise, not content opportunities.

**Recurring theme check:** First run — no cross-run comparison available. GLP-1 / Ozempic and pediatric mental health are flagged as likely recurring themes in future runs.

**Deferred topics:** No past-due deferred topics found. Recommend adding to deferred queue: PCOS nutrition center (recheck in 7 days if news develops), Brian Johnson health/longevity (recheck if specific peer-reviewed study published), Fentanyl vaccine (recheck if ClinicalTrials.gov record or institutional press release published).

**Signal quality note:** "wellness" Google Trends rising queries were heavily polluted by spam/SEO farm domains in the related-query data. This is a known Google Trends artifact for broad head terms. Treat "wellness" Trends data as low-signal; narrow to specific topic-level queries for future runs.

**Dashboard:** Outputs saved to `outputs/daily_newsroom_dashboard/2026-07-12.html` (pending file write).

**Run history entry added to `data/run_history.yaml`:**
```
Run Date: 2026-07-12 | Niche: Health & Wellness | Signals Reviewed: 144 |
Topics Retained: 9 | Topics Rejected: 23 | P1: 3 | P2: 3 | P3: 3 |
Integrity Flags: 9 | Top Topic: FDA Eye Drop Recall |
Key Themes: FDA recalls, GLP-1 safety, sleep/weight research, opioid tapering, Ebola DRC |
Tools Used: SerpAPI pre-fetch (Google News + Google Trends) |
Tools Unavailable: None | Notes: First run; no site_url; self-check skipped.
```